肺小细胞癌的组织学亚型:对治疗的反应

Stephen Davis , Harold Sobel
{"title":"肺小细胞癌的组织学亚型:对治疗的反应","authors":"Stephen Davis ,&nbsp;Harold Sobel","doi":"10.1016/0014-2964(81)90127-4","DOIUrl":null,"url":null,"abstract":"<div><p>Seventy-seven patients with extensive small cell carcinoma of the lung were initially treated with the same combination chemotherapy consisting of cyclophosphamide and doxorubicin. All cases were retrospectively subdivided according to their histological subtype as proposed by the World Health Organization Lung Cancer Classification (WHO): the classic lymphocyte-like (oat cell), type <em>21</em>, and intermediate cell, type <em>22</em>. Type <em>21</em> has an objective response rate of <em>43%</em> and type <em>22</em> a response rate of <em>23%</em>. Analysis of the data revealed that the median survival for WHO type <em>21</em> was <em>30.4</em> weeks; whereas median survival for type <em>22</em> was <em>17.2</em> weeks (P = <em>0.04</em>). This difference in subtype response was also seen when response was corrected for Karnofsky initial performance status <em>40–70</em> but not for performance status <em>80–100</em>. Type <em>21</em> small cell carcinoma appears to offer a higher response rate to chemotherapy and a longer survival than type <em>22</em>.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 3","pages":"Pages 351-354"},"PeriodicalIF":0.0000,"publicationDate":"1981-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90127-4","citationCount":"4","resultStr":"{\"title\":\"Histologic subtypes of small cell carcinoma of the lung: Response to therapy\",\"authors\":\"Stephen Davis ,&nbsp;Harold Sobel\",\"doi\":\"10.1016/0014-2964(81)90127-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Seventy-seven patients with extensive small cell carcinoma of the lung were initially treated with the same combination chemotherapy consisting of cyclophosphamide and doxorubicin. All cases were retrospectively subdivided according to their histological subtype as proposed by the World Health Organization Lung Cancer Classification (WHO): the classic lymphocyte-like (oat cell), type <em>21</em>, and intermediate cell, type <em>22</em>. Type <em>21</em> has an objective response rate of <em>43%</em> and type <em>22</em> a response rate of <em>23%</em>. Analysis of the data revealed that the median survival for WHO type <em>21</em> was <em>30.4</em> weeks; whereas median survival for type <em>22</em> was <em>17.2</em> weeks (P = <em>0.04</em>). This difference in subtype response was also seen when response was corrected for Karnofsky initial performance status <em>40–70</em> but not for performance status <em>80–100</em>. Type <em>21</em> small cell carcinoma appears to offer a higher response rate to chemotherapy and a longer survival than type <em>22</em>.</p></div>\",\"PeriodicalId\":100497,\"journal\":{\"name\":\"European Journal of Cancer (1965)\",\"volume\":\"17 3\",\"pages\":\"Pages 351-354\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0014-2964(81)90127-4\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer (1965)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0014296481901274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer (1965)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0014296481901274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

摘要

77例肺广泛小细胞癌患者最初接受由环磷酰胺和阿霉素组成的相同联合化疗。根据世界卫生组织肺癌分类(WHO)提出的组织学亚型对所有病例进行回顾性细分:经典淋巴细胞样(燕麦细胞)21型和中间细胞22型。21型的客观反应率为43%,22型的反应率为23%。数据分析显示,WHO 21型的中位生存期为30.4周;而22型患者的中位生存期为17.2周(P = 0.04)。当Karnofsky初始成绩状态40-70而80-100的反应被纠正时,也可以看到这种亚型反应的差异。21型小细胞癌似乎比22型对化疗有更高的反应率和更长的生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Histologic subtypes of small cell carcinoma of the lung: Response to therapy

Seventy-seven patients with extensive small cell carcinoma of the lung were initially treated with the same combination chemotherapy consisting of cyclophosphamide and doxorubicin. All cases were retrospectively subdivided according to their histological subtype as proposed by the World Health Organization Lung Cancer Classification (WHO): the classic lymphocyte-like (oat cell), type 21, and intermediate cell, type 22. Type 21 has an objective response rate of 43% and type 22 a response rate of 23%. Analysis of the data revealed that the median survival for WHO type 21 was 30.4 weeks; whereas median survival for type 22 was 17.2 weeks (P = 0.04). This difference in subtype response was also seen when response was corrected for Karnofsky initial performance status 40–70 but not for performance status 80–100. Type 21 small cell carcinoma appears to offer a higher response rate to chemotherapy and a longer survival than type 22.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Books received Estrogen receptor assay: Interlaboratory and intralaboratory variations in the measurement of receptors using dextran-coated charcoal technique: A study sponsored by E.C.O.G. Herpes Simplex Virus and human cancer. I. Relationship between human cervical tumours and Herpes Simplex Type 2 Herpes Simplex Virus and human cancer. II. Search for relationship between labial tumours and Herpes Simplex Type 1 Immunological properties of rat embryonal carcinoma cells
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1